evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

254 questions · 276 findings · 23 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 62 · 22.5%GRADE not reported 88 · 31.9%Very low 43 · 15.6%Low 43 · 15.6%Moderate 36 · 13%High 4 · 1.4%

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

9 findings from 1 review
Show 6 more findings

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma

External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).

1 finding from 1 review

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma

External beam radiotherapy (EBRT) plus transarterial… may leads to higher complete response plus partial response Length of compared with TACE alone (low certainty).

1 finding from 1 review

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Elevated alanine aminotransferase Length of · participants with unresectable hepatocellular carcinoma

It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated alanine aminotransferase Length of compared with TACE alone (very low certainty).

1 finding from 1 review

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Elevated total bilirubin Length of · participants with unresectable hepatocellular carcinoma

It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated total bilirubin Length of compared with TACE alone (very low certainty).

1 finding from 1 review